Pharmacogenetics and drug development: the path to safer and more effective drugs (original) (raw)

• Cardon, L. R. & Bell, J. I. Association study designs for complex diseases. Nature Rev. Genet. 2, 91–99 (2001). An informative review of the application of genetic association methods used to identify genes associated with complex diseases.
  Article CAS Google Scholar
• Tabor, H. K., Risch, N. J. & Myers, R. M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nature Rev. Genet. 3, 391–397 (2002).
  Article CAS Google Scholar
• Weiss, K. M. & Clark, A. G. Linkage disequilibrium and the mapping of complex human traits. Trends Genet. 18, 19–24 (2002). An overview of the applications of LD mapping for diseases, but equally applicable to safety (adverse-event) PGx.
  Article CAS Google Scholar
• Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. Pharmacogenetics goes genomic. Nature Rev. Genet. 4, 937–947 (2003).
  Article CAS Google Scholar
• Carlson, C. S. et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74, 106–120 (2004).
  Article CAS Google Scholar
• Dawson, E. et al. A first-generation linkage disequilibrium map of human chromosome 22. Nature 418, 544–548 (2002).
  Article CAS Google Scholar
• Lai, E. et al. Medical applications of haplotype-based SNP maps: learning to walk before we run. Nature Genet. 32, 353 (2002). Comment on the difference between a strategy of whole-genome mapping, limited to a full panel of small, well-defined LD blocks, versus the use of an initial screening set to determine regions of extended LD for fine mapping (for examples see references 10, 16 and 47).
  Article CAS Google Scholar
• Roses, A. D. Pharmacogenetics. Hum. Mol. Genet. 10, 2261–2267 (2001).
  Article CAS Google Scholar
• Roses, A. D. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541–554 (2002).
  Article CAS Google Scholar
• Xu, C. F. et al. Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J. (in the press). A proof of principle analysis of the application of whole-genome LD to map a locus (loci) associated with an adverse effect of a medicine.
• Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [online], <http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html> (2004).
• Lindsay, M. A. Target discovery. Nature Rev. Drug Discov. 2, 831–838 (2003).
  Article CAS Google Scholar
• Chanda, S. K. & Caldwell, J. S. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8, 168–174 (2003).
  Article CAS Google Scholar
• Collins, F. S. Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics 54, 410–417 (1999).
  Google Scholar
• Subramanian, G., Adams, M. D., Venter, J. C. & Broder, S. Implications of the human genome for understanding human biology and medicine. JAMA 286, 2296–2307 (2001).
  Article CAS Google Scholar
• McCarthy, L. C. et al. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78, 135–149 (2001). An early example of the use of high density SNP mapping in a region of putative genetic linkage, in this case for the identification of specific SNP variants of the insulin receptor gene that are associated with migraine.
  Article CAS Google Scholar
• Hakonarson, H., Gulcher, J. R. & Stefansson, K. deCODE genetics, Inc. Pharmacogenomics 4, 209–215 (2003).
  Article Google Scholar
• Kristjansson, K. et al. Linkage of essential hypertension to chromosome 18q. Hypertension 39, 1044–1049 (2002).
  Article CAS Google Scholar
• Nathan, D. G. Clinical research: perceptions, reality, and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA 280, 1427–1431 (1998).
  Article CAS Google Scholar
• Boston Consulting Group. A Revolution in R&D: How Genomics and Genetics Will Affect Drug Development Costs and Tmes in Parexel's Pharmaceutical R&D Statistical Sourcebook, 2003/2003 (Parexel International, Waltham, USA, 2003).
• Harris, S. & Foord, S. M. Transgenic gene knock-outs: functional genomics and therapeutic target selection. Pharmacogenomics 1, 433–443 (2000).
  Article CAS Google Scholar
• Brenner, S. E. Target selection for structural genomics. Nature Struct. Biol. 7 (Suppl.), 967–969 (2000).
  Article CAS Google Scholar
• DeFife, K. M. & Wong-Staal, F. Integrated approaches to therapeutic target gene discovery. Curr. Opin. Drug Discov. Dev. 5, 683–689 (2002).
  CAS Google Scholar
• Searls, D. B. Pharmacophylogenomics: genes, evolution and drug targets. Nature Rev. Drug Discov. 2, 613–623 (2003). An analysis of the importance of placing genomic variation in an evolutionary context, taking advantage of phylogenetic relationships and comparisons, to better understand function and in particular selective pressures.
  Article CAS Google Scholar
• Debouck, C. & Metcalf, B. The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 193–207 (2000).
  Article CAS Google Scholar
• Drews, J. Drug discovery: a historical perspective. Science 287, 1960–1964 (2000).
  Article CAS Google Scholar
• Thorisson, G. A. & Stein L. D. The SNP Consortium website: past, present and future. Nucleic Acids Res. 31, 124–127 (2003).
  Article CAS Google Scholar
• Vaschetto, M., Weissbrod, T., Bodle, D. & Guner, O. Enabling high-throughput discovery. Curr. Opin. Drug Discov. Dev. 6, 377–383 (2003).
  CAS Google Scholar
• Duyk, J. Attrition and translation. Science 302, 603–605 (2003).
  Article CAS Google Scholar
• Twyman, R. M. & Primrose, S. B. Techniques patents for SNP genotyping. Pharmacogenomics 4, 67–79 (2003).
  Article CAS Google Scholar
• Renegar, G., Rieser, P. & Manasco, P. Family consent and the pursuit of better medicines through genetics research. J. Contin. Educ. Health Prof. 21, 265–270 (2001).
  Article CAS Google Scholar
• Horrobin, D. F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nature Rev. Drug Discov. 2, 151–154 (2003).
  Article CAS Google Scholar
• Roses, A. D. High through-put disease-associated target identification. Drug Discov. Today (in the press). Description of high throughput multi-gene target testing to determine variants that are highly associated with human disease.
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS Google Scholar
• Dos Santos, C. et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genet. 36, 720–724 (2004).
  Article CAS Google Scholar
• Tantisira, K. G. et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13, 1353–1359 (2004).
  Article CAS Google Scholar
• Sesti, G. et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27, 1394–1398 (2004).
  Article CAS Google Scholar
• Macedo, A., Farre, M. & Banos, J. E. Placebo effect and placebos: what are we talking about? Some conceptual and historical considerations. Eur. J. Clin. Pharmacol. 59, 337–342 (2003).
  Article Google Scholar
• Goetz, C. G., Janko, K., Blasucci, L. & Jaglin, J. A. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov. Disord. 18, 1146–1149 (2003).
  Article Google Scholar
• Anonymous. The Fruits of Genomics: Drug Pipelines Face Indigestion Until the New Biology Ripens. (Lehman Brothers, McKinsey and Co., New York, 2001).
• Tufts Center for the Study of Drug Development. Backgrounder: How New Drugs Move Through the Development and Approval Process <http://csdd.tufts.edu/NewsEvents?RecentNews.asp?newsid=4> (2001).
• Gilbert, J., Henkse, P. & Singh, A. Rebuilding big pharma's business model. In vivo, the business and medicine report. Windhover Information, 21, No. 10, (2003).
• Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800–1805 (2004).
  Article CAS Google Scholar
• Vogel, C. L. & Franco S. X. Clinical experience with trastuzumab (herceptin). Breast J. 9, 452–462 (2003).
  Article CAS Google Scholar
• Goldstein, D. B., Ahmadi, K. R., Weale, M. E. & Wood N. W. Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends Genet. 19, 615–622 (2003).
  Article CAS Google Scholar
• Lai, E., Riley, J., Purvis, I. & Roses, A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54, 31–38 (1998). An early example of LD mapping of a region of genetic linkage to demonstrate the polymorphisms of SLC12A8, a gene coding for a member of the solute carrier family 12 proteins that are associated with familial psoriasis.
  Article CAS Google Scholar
• Hewett, D. et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79, 305–314 (2002).
  Article CAS Google Scholar
• deCODE Genetics. deCODE and Merck & Co., Inc. form broad drug development alliance. deCODE News [online], <http://www.decode.com/main/view.jsp?branch=5026&e342RecordID=1901&e342DataStoreID=3917> (2004).
• Merck Press Release. Drug development; pharmaceutical company joins drug development alliance. Genomics & Genetics Weekly 38, (2004).
• Melzer, D., Detmer, D. & Simmern, R. Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 4, 689–691 (2003).
  Article Google Scholar
• Lee, S. S. Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am. J. Pharmacogenomics 3, 385–392 (2003).
  Article Google Scholar
• Hapgood, R. The potential and limitations of personalized medicine in the doctor-patient relationship. Pharmacogenomics 4, 685–687 (2003).
  Article Google Scholar
• Drazen, J. M. et al. Pharmacogenetic association between ALOEX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (2003).
  Article Google Scholar
• Wechsler, M. E. & Israel, E. Pharmacogenetics of treatment with leukotriene modifiers. Curr. Opin. Allergy Clin. Immunol. 2, 395–401 (2002).
  Article Google Scholar
• Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001).
  Article CAS Google Scholar
• Roses, A. D. 2025: the practice of neurology: back from the future. Arch. Neurol. 58, 1766–1767 (2001).
  Article CAS Google Scholar
• Ahmadi, K. R. et al. A single nucleotide polymorphism tagging set for human drug metabolism and transport. Science (in the press). A study and analysis of the use of LD mapping to determine a tagged set of SNPs for 56 human drug metabolizing enzymes.
• Griffiths, J. D., Stark, R. J., Ding, J. C. & Cooper, I. A. Vincristine neurotoxicity in Charcot–Marie–Tooth syndrome. Med. J. Aust. 143, 305–306 (1985).
  CAS PubMed Google Scholar
• Danoff, T. M. et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49–53 (2004).
  Article CAS Google Scholar
• Gibbs, R. A. et al. The International HapMap Project. Nature 426, 789–796 (2003).
  Article CAS Google Scholar
• Bowman, C. Classification using SNP profiles. <http://www.luc.ac.be/censtat/RSS2003> (2003).
• Norbert, P. W. & Roses A. D. Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. J. Mol. Med. 81, 35–40 (2003).
  Google Scholar
• Lesko, L. J. et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J. Clin. Pharmacol. 43, 342–358 (2003). A view from the FDA, the agency that regulates pharmaceutical licenses in the US, on decision making using pharmacogenetics and pharmacogenomics during drug development, including definition of key terms generically referred to as “biomakers.”
  Article CAS Google Scholar
• Buchanan, A. et al. Pharmacogenetics: ethical issues and policy options. Kennedy Inst. Ethics J. 12, 1–15 (2002).
  Article Google Scholar
• Welsh-Bohmer, K. A. et al. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Ann. Neurol. 42, 319–325 (1997).
  Article CAS Google Scholar